The only validated test to help inform your decision to extend or end endocrine therapy

Select a patient to read a full case.

Breast Cancer Index Use Along Care Continuum

Diagnosis

FOR PATIENTS:

  • Struggling with tolerability challenges
  • Who are poorly compliant

WITH QUESTIONS:

  • "How long do I need to take this pill?"

BCI MAY HELP:

  • Provide clarity on treatment road-map (5 or 10 years); encourage compliance
5 Year

  • All patients approaching 5 year anniversary
    (4-5 years post-diagnosis)

  • "Should I continue treatment for another 5 years?"

  • Further inform whether to extend or end endocrine treatment beyond 5 years
10 Year

  • All patients 5-9 years post-diagnosis who are either:
    - Already on extended endocrine treatment
    - Have already stopped endocrine therapy after completing 5 years.

  • "Since there is new clinical data is there more for us to consider?"
  • "Are there other tests to help tell us if this treatmnt is right for me?"

  • Further inform previous decision related to extended endocrine treatment:
    - To continue
    - To restart
Breast Cancer Index Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.

This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.